发明名称 |
Controlled release valproate composition |
摘要 |
<p>An oral controlled release composition, including a valproate compound, suitable for once-a-day administration characterized in that when said composition is ingested orally, said composition produces a valproate Cmax that is statistically significantly lower than the valproate Cmax produced by a delayed release divalproex sodium tablet, when each is determined at steady state in a fasting population. This composition minimizes the variation between peak and trough plasma levels of valproate over a 24 hour dosing period. This composition follows a zero-order release pattern thus producing essentially flat plasma levels of valproate, once steady-state levels have been achieved. This results in a significantly lower incidence of side effects for patients consuming such a composition. <IMAGE></p> |
申请公布号 |
EP1216704(B1) |
申请公布日期 |
2004.09.08 |
申请号 |
EP20010310755 |
申请日期 |
2001.12.21 |
申请人 |
ABBOTT LABORATORIES |
发明人 |
QIU, YIHONG;BOLLINGER, DANIEL J.;DUTTA, SANDEEP;CHESKIN, HOWARD S.;ENGH, KEVIN R.;POSKA, RICHARD P.;SOMMERVILLE, KENNETH W. |
分类号 |
A61K9/20;A61K9/22;A61K31/19;A61P25/06;A61P25/08;A61P25/18;(IPC1-7):A61K31/19 |
主分类号 |
A61K9/20 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|